Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03164057 · ClinicalTrials.gov registry record · Phase 2
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 2 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
- 10
- Study locations
NCT03164057 is a Phase 2 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 206 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (79% higher). The trial reports 10 study locations across 7 states.
The verdict
NCT03164057, a Phase 2 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
- 10
- Study locations
Study Summary
The overall aim of this study is to determine if epigenetic priming with a DNA methyltransferase inhibitor (DMTi) prior to chemotherapy blocks is tolerable and carries evidence of a clinical efficacy signal as determined by minimal residual disease (MRD), event-free survival (EFS), and overall survival (OS). Tolerability for each of the agents, as well as total reduction in DNA methylation and outcome assessments will be done to simultaneously obtain preliminary biological and clinical data for each DMTi in parallel. PRIMARY OBJECTIVES: * Evaluate the tolerability of five days of epigenetic priming with azacitidine and decitabine as a single agent DMTi prior to standard AML chemotherapy blocks. * Evaluate the change in genome-wide methylation burden induced by five days of epigenetic priming and the association of post-priming genome-wide methylation burden with event-free survival among pediatric AML patients. SECONDARY OBJECTIVES * Describe minimal residual disease levels following Induction I chemotherapy in patients that receive DMTi. * Estimate the event-free survival and overall survival of patients receiving a DMTi prior to chemotherapy courses.
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Decitabine
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Daunorubicin
Study Locations (10)
California
- Children's Hospital of Central California - Madera
- Children's Hospital of Orange County - Orange
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- Rady Children's Hospital and Health Center - San Diego
Illinois
- University of Chicago Children's Hospital (Comer) - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Children's Hospital of Michigan - Detroit
South Dakota
- Sanford Children's Specialty Clinic - Sioux Falls
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- Cook Children's Medical Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03164057
The ClinicalTrials.gov registry entry for NCT03164057 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (79% higher). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Azacitidine is the first listed.
NCT03164057 reports 10 study locations spanning 7 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03164057 about?
NCT03164057 is a clinical study titled "A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia". The overall aim of this study is to determine if epigenetic priming with a DNA methyltransferase inhibitor (DMTi) prior to chemotherapy blocks is tolerable and carries evidence of a clinical efficacy signal as determined by minimal residual disease (MRD), event-free survival (EFS), and overall survi...
What is the current status of trial NCT03164057?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2017-06-15. Estimated completion is 2027-06.
What conditions does trial NCT03164057 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes.
What interventions are being tested in trial NCT03164057?
The interventions under investigation include: Azacitidine (DRUG), Decitabine (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG).
Who is sponsoring clinical trial NCT03164057?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03164057 being conducted?
This trial has 10 study locations across California, Illinois, Massachusetts, Michigan, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.